Advanced Dermatology and Cosmetic Surgery - Spartanburg (South Carolina)

866-269-0309

Research Studies at Spartanburg, South Carolina

Advanced Dermatology and Cosmetic Surgery
1650 Skylyn Dr, Ste 402
Spartanburg, SC 29307

Submit Your Interest

 

Generalized Pustular Psoriasis (GPP) 

Males and Females, Ages 18+ years old. Qualifying patients will have been diagnosed with Generalized Pustular Psoriasis (GPP).

GPP is a rare, severe form of pustular psoriasis. It is characterized by sudden widespread eruption of rash and sterile pustules with or without systemic inflammation and erythematous, painful skin. GPP can be associated with systemic inflammation including fevers and/or hepatic, gastrointestinal, musculoskeletal, renal, or pulmonary involvement.

 

Study Details

This is a prospective, observational registry that seeks to obtain information on the treatment patterns, and adverse events in a cohort of GPP patients. Data collected will be used to better characterize the natural history and longitudinal trajectory of the disease. This will be done through the standardized collection of validated patient-reported outcomes (PRO) and clinician-reported outcomes (ClinRO), the active evaluation of prevalent and incident comorbidities and adverse events, and the recording of medication utilization patterns.

Compensation: $25 per completed visit
Duration: Every 6 monts
Visits: 12

 

Alopecia Areata (Hair Loss)

Males and Females, Ages 18+ years old. Qualifying patients will have Alopecia Areata (AA) diagnosed at least 6 months ago and been prescribed a new medication within the past 12 months.

Alopecia Areata (AA) is an autoimmune disease that causes hair loss due to the immune system attacking hair follicles. It typically presents with discrete bald patches on the scalp but can affect all hair-bearing areas on the body. The exact cause is unclear, but it involves a loss of immune privilege in hair follicles, allowing autoantigens to be presented to autoreactive CD8+ T cells. Risk factors include certain susceptibility genes, family history of autoimmune disorders, and genetic makeup. 

 

Study Details

This is a prospective, observational registry study that seeks to create a cohort of AA patients to study the long-term safety and effectiveness of AA medications. Further, data collected will inform clinical decision making by patients and treating providers. This will be done through the standardized collection of validated patient-reported outcomes (PRO) and clinician-reported outcomes (ClinRO), the active evaluation of prevalent and incident comorbidities and adverse events, and the recording of medication utilization patterns.

Compensation: $25 per completed visit
Duration: Every 6 months
Visits: 12

 

Alopecia Areata (Hair Loss)

Male and Female Adolescents, Ages 12 to 17 years old. Qualifying patients will have Alopecia Areata (AA).

Severe alopecia areata is an autoimmune disease that attacks the body’s hair follicles, causing patchy hair loss. While it doesn’t typically affect physical health, it can be mentally and emotionally challenging, especially adolescents already struggling with their changing self-identity and social expectations.   

 

Study Details

This study evaluates the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair loss. This study begins with a double-blind, randomized, placebo-controlled Treatment Period of 24 weeks. It is a 4:1 placebo ratio. After 24 weeks, all subjects will receive Deuruxolitinib for 52 weeks. The study drug, study-related procedures, and study visits will be provided at no charge to you or your insurance company. 

Compensation: $100 per completed visit
Duration: Up to 84 weeks (about 1.5 years)
Visits: 18

 

Atopic Dermatitis (Eczema)

Males and Females, Ages 12+. Qualifying patients will have diagnosed Atopic Dermatitis (AD) and prescribed to initiate a new systemic treatment for AD during their office visit at the Advanced Dermatology and Cosmetic Surgery location in Spartanburg.

AD is a chronic, relapsing inflammatory skin disease that significantly burdens the patient’s quality of life. To qualify for this study, patients will be switched or initiated on a new systemic treatment (such as biologics, oral Janus kinase (JAK) inhibitors, cyclosporine, azathioprine, methotrexate, mycophenolate mofetil) by a qualified healthcare provider.

 

Study Details

The objectives of this prospective non-interventional study are to characterize the existing unmet needs across the spectrum of atopic dermatitis (AD), enhance the understanding of the patient journey, and evaluate the safety and clinical outcomes of systemic AD treatments in a real-world setting. Additionally, patient-specific factors (such as age, skin color, AD flare triggers, previous treatment responses, comorbid conditions, and the extent and site of lesions) will be assessed to better characterize the impact on the treatment journey across a broad age range and diverse geographic regions.

Compensation: $72-$80 per completed visit
Duration: Every 3-6 months, 60 months total
Visits: 13

 

Atopic Dermatitis (Eczema)

Males and Females, Ages 12+. Qualifying patients will have moderate to severe atopic dermatitis (eczema) diagnosed at least 6 months ago. 

AD is a chronic, relapsing inflammatory skin disease that significantly burdens the patient’s quality of life. Lebrikizumab is a systemic, novel, subcutaneously injected IgG4 monoclonal antibody selectively targeting Interleukin-13 with high binding affinity and slow off-rate, as demonstrated by efficacy and safety in patients with moderate-to-severe AD in clinical studies.

 

Study Details

This is an observational study that seeks to understand the effects of lebrikizumab therapy on the treatment of pediatric and adult participants diagnosed with moderate-to-severe Atopic Dermatitis (AD). The research study will involve 8 study visits over the course of 24 months. Since this is an observational study, visits will align with routine care and subjects will only be required to fill out surveys and perform assessments during their visits.

Compensation: $672
Duration: 24 Weeks
Visits: 8

 

Atopic Dermatitis (Eczema)

Males and Females, Ages 12+. Qualifying patients will have moderate to severe atopic dermatitis (eczema) diagnosed at least 6 months ago. 

AD is a chronic, relapsing inflammatory skin disease that significantly burdens the patient’s quality of life. 

 

Study Details

This prospective, multicenter, non-interventional study (NIS) seeks to evaluate treatment with nemolizumab of moderate-to-severe AD in adolescents and adults over an approximately 12-month period using physician assessments in routine clinical practice and PRO measures. Treatment with nemolizumab will be determined solely by the participant's physician prior to study enrollment. No additional visits, procedures, or laboratory tests are required outside of routine clinical practice. 

Compensation: $25 per visit
Duration: 12 Months
Visits: 5

 

Prurigo Nodularis (PN) 

Males and Females, Adults 18+. Qualifying patients will have a diagnosis of prurigo nodularis for at least 6 months prior to screening. 

Prurigo Nodularis is a chronic inflammatory skin disease that persistently causes intense itching and skin papules or nodules on certain areas of the skin – especially on arms, legs, or trunk. The disease at any age but is more commonly observed in middle-aged to elderly individuals and people with colored skin. Prurigo Nodularis is not contagious.

 

Study Details

This prospective, multicenter, non-interventional study (NIS) seeks to evaluate PN treatment with nemolizumab (Nemluvio®) in adults over an approximately 12-month period using physician assessments in routine clinical practice and PRO measures. Treatment with nemolizumab will be determined solely by the participant's physician prior to study enrollment. No additional visits, procedures, or laboratory tests are required outside of routine clinical practice. 

Compensation: $25
Duration: 12 Months
Visits: 5

 

Please select the study indication(s) you are interested in
Immediate appointments available at many of our 150+ Locations

BOOK AN APPOINTMENT 866-400-3376

Cosmetics/aesthetics 800-647-9851

Added to Cart​

Checkout​

Images are loading, please wailt a minute.

Thank you for reaching out. Our staff will contact you within 24 hours!
Cannot submit your request. Please try again later
close popup